Sangamo Therapeutics

Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.[1]

Sangamo Therapeutics
Public
Traded asNASDAQ: SGMO
Russell 2000 Index component
IndustryBiotechnology
Founded1995
Headquarters
Brisbane, California, U.S.
Key people
Sandy Macrae (CEO)
Edward Rebar (CTO)
Number of employees
182
Websitesangamo.com
President and CEO Sandy Macrae in 2018

History

The company was founded in 1995 in Richmond, California.[2] It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees.[2] Sandy Macrae is the president.[3] In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.[4]

Research

Sangamo applies technology to treat haemophilia B and lysosomal storage diseases including mucopolysaccharidosis type I (Hurler Syndrome) and mucopolysaccharidosis type II (Hunter Syndrome). The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A. In its partnership with Pfizer in 2017,[5] Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease.[1] It is also developing zinc finger gene editing technology.[6]

In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter Syndrome.[7] Clinical trials by Sangamo involving gene editing using Zinc Finger Nuclease (ZFN) are ongoing.[8]

See also

References
  1. McConaghie, Andrew (May 17, 2017). "Sangamo and new gene therapy partner Pfizer lifted by FDA fast track". Pharmaphorum. Retrieved October 1, 2018.
  2. "Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04". Equities. September 8, 2018. Retrieved October 1, 2018.
  3. Ledford, Heidi (September 5, 2018). "First test of in-body gene editing shows promise". Nature. doi:10.1038/d41586-018-06195-6. ISSN 0028-0836.
  4. "Sangamo Therapeutics appoints Edward Rebar as senior vice president". Post Online Media. Richmond, California. July 16, 2018. Retrieved October 1, 2018.
  5. "SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY | Pfizer". www.pfizer.com. Retrieved April 22, 2020.
  6. Renauer, Cory (September 6, 2018). "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?". The Motley Fool. Retrieved October 1, 2018.
  7. Marchione, Marilyn (February 7, 2019). "Tests suggest scientists achieved 1st 'in body' gene editing". AP News. Retrieved February 7, 2019.
  8. Staff (February 2, 2019). "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II". ClinicalTrials.gov. U.S. National Library of Medicine. Retrieved February 7, 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.